Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Advanced malignancies
Pevonedistat
Pharmacokinetics [4 to 6 max]
Rifampin
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
06
05
2022
accepted:
11
07
2022
pubmed:
7
8
2022
medline:
25
8
2022
entrez:
6
8
2022
Statut:
ppublish
Résumé
Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase 1 study evaluating the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics (PK) of pevonedistat in patients with advanced solid tumors (NCT03486314). Patients received a single 50 mg/m
Identifiants
pubmed: 35932388
doi: 10.1007/s10637-022-01286-8
pii: 10.1007/s10637-022-01286-8
pmc: PMC9395450
doi:
Substances chimiques
Cyclopentanes
0
Enzyme Inhibitors
0
NEDD8 Protein
0
NEDD8 protein, human
0
Pyrimidines
0
pevonedistat
S3AZD8D215
Rifampin
VJT6J7R4TR
Banques de données
ClinicalTrials.gov
['NCT03486314']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1042-1050Informations de copyright
© 2022. The Author(s).
Références
Wolenski FS, Fisher CD, Sano T et al (2015) The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. Cell death discovery 1:15034. https://doi.org/10.1038/cddiscovery.2015.34
doi: 10.1038/cddiscovery.2015.34
pubmed: 27551465
pmcid: 4979425
Swords RT, Coutre S, Maris MB et al (2018) Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131(13):1415–1424. https://doi.org/10.1182/blood-2017-09-805895
doi: 10.1182/blood-2017-09-805895
pubmed: 29348128
pmcid: 5909884
Zhou L, Zhang W, Sun Y, Jia L (2018) Protein neddylation and its alterations in human cancers for targeted therapy. Cell Signal 44:92–102. https://doi.org/10.1016/j.cellsig.2018.01.009
doi: 10.1016/j.cellsig.2018.01.009
pubmed: 29331584
pmcid: 5829022
Zhou L, Jiang Y, Luo Q, Li L, Jia L (2019) Neddylation: a novel modulator of the tumor microenvironment. Mol Cancer 18(1):77. https://doi.org/10.1186/s12943-019-0979-1
doi: 10.1186/s12943-019-0979-1
pubmed: 30943988
pmcid: 6446326
Abidi N, Xirodimas DP (2015) Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic. Endocr Relat Cancer 22(1):T55-70. https://doi.org/10.1530/erc-14-0315
doi: 10.1530/erc-14-0315
pubmed: 25504797
Jiang Y, Jia L (2015) Neddylation pathway as a novel anti-cancer target: mechanistic investigation and therapeutic implication. Anticancer Agents Med Chem 15(9):1127–1133. https://doi.org/10.2174/1871520615666150305111257
doi: 10.2174/1871520615666150305111257
pubmed: 25742093
Soucy TA, Smith PG, Rolfe M (2009) Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 15(12):3912–3916. https://doi.org/10.1158/1078-0432.CCR-09-0343
doi: 10.1158/1078-0432.CCR-09-0343
pubmed: 19509147
Milhollen MA, Traore T, Adams-Duffy J et al (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-(kappa)B-dependent lymphoma. Blood 116(9):1515–1523. https://doi.org/10.1182/blood-2010-03-272567
doi: 10.1182/blood-2010-03-272567
pubmed: 20525923
Swords RT, Kelly KR, Smith PG et al (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115(18):3796–3800. https://doi.org/10.1182/blood-2009-11-254862
doi: 10.1182/blood-2009-11-254862
pubmed: 20203261
Bhatia S, Pavlick AC, Boasberg P et al (2016) A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Invest New Drugs 34(4):439–449. https://doi.org/10.1007/s10637-016-0348-5
doi: 10.1007/s10637-016-0348-5
pubmed: 27056178
pmcid: 4919369
Lockhart AC, Bauer TM, Aggarwal C et al (2019) Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs 37(1):87–97. https://doi.org/10.1007/s10637-018-0610-0
doi: 10.1007/s10637-018-0610-0
pubmed: 29781056
Sarantopoulos J, Shapiro GI, Cohen RB et al (2016) Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors. Clin Cancer Res 22(4):847–857. https://doi.org/10.1158/1078-0432.CCR-15-1338
doi: 10.1158/1078-0432.CCR-15-1338
pubmed: 26423795
Shah JJ, Jakubowiak AJ, O’Connor OA et al (2016) Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma. Clin Cancer Res 22(1):34–43. https://doi.org/10.1158/1078-0432.CCR-15-1237
doi: 10.1158/1078-0432.CCR-15-1237
pubmed: 26561559
Zhou X, Sedarati F, Faller DV et al (2021) Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Invest New Drugs 39(2):488–498. https://doi.org/10.1007/s10637-020-01017-x
doi: 10.1007/s10637-020-01017-x
pubmed: 33089874
Faessel HM, Mould DR, Zhou X et al (2019) Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol 85(11):2568–2579. https://doi.org/10.1111/bcp.14078
doi: 10.1111/bcp.14078
pubmed: 31355467
pmcid: 6848912
Faessel H, Nemunaitis J, Bauer TM et al (2019) Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. Br J Clin Pharmacol 85(7):1464–1473. https://doi.org/10.1111/bcp.13915
doi: 10.1111/bcp.13915
pubmed: 30845347
pmcid: 6595297
Cotreau MM, Siebers NM, Miller J, Strahs AL, Slichenmyer W (2015) Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Clin Pharmacol Drug Dev 4(2):137–142. https://doi.org/10.1002/cpdd.145
doi: 10.1002/cpdd.145
pubmed: 27128217
Gupta N, Hanley MJ, Venkatakrishnan K et al (2018) Effects of strong CYP3A inhibition and induction on the pharmacokinetics of ixazomib, an oral proteasome inhibitor: results of drug-drug interaction studies in patients with advanced solid tumors or lymphoma and a physiologically based pharmacokinetic analysis. J Clin Pharmacol 58(2):180–192. https://doi.org/10.1002/jcph.988
doi: 10.1002/jcph.988
pubmed: 28800141
Faucette S, Wagh S, Trivedi A, Venkatakrishnan K, Gupta N (2018) Reverse translation of US Food and Drug Administration reviews of oncology new molecular entities approved in 2011–2017: lessons learned for anticancer drug development. Clin Transl Sci 11(2):123–146. https://doi.org/10.1111/cts.12527
doi: 10.1111/cts.12527
pubmed: 29266809
Bullock JM, Lin T, Bilic S (2017) Clinical pharmacology tools and evaluations to facilitate comprehensive dose finding in oncology: a continuous risk-benefit approach. J Clin Pharmacol 57(Suppl 10):S105-s115. https://doi.org/10.1002/jcph.908
doi: 10.1002/jcph.908
pubmed: 28921642
Varma MV, Lai Y, Feng B et al (2012) Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29(10):2860–2873. https://doi.org/10.1007/s11095-012-0792-7
doi: 10.1007/s11095-012-0792-7
pubmed: 22638872
ACCP Abstract Booklet (2021) Clinical Pharmacology in Drug Development. 10(S1):1–104. https://doi.org/10.1002/cpdd.1004